Y. Ohe

421 total citations · 1 hit paper
12 papers, 326 citations indexed

About

Y. Ohe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Y. Ohe has authored 12 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Y. Ohe's work include Lung Cancer Treatments and Mutations (8 papers), RNA modifications and cancer (5 papers) and Lung Cancer Research Studies (3 papers). Y. Ohe is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), RNA modifications and cancer (5 papers) and Lung Cancer Research Studies (3 papers). Y. Ohe collaborates with scholars based in Japan, United States and United Kingdom. Y. Ohe's co-authors include J. Carl Barrett, Jhanelle E. Gray, Yi Cheng, Suresh S. Ramalingam, Riyaz Shah, C. Zhou, Fumio Imamura, Aleksandra Markovets, Yuri Rukazenkov and A. Todd and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Lung Cancer.

In The Last Decade

Y. Ohe

11 papers receiving 321 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

2018 269 citations Suresh S. Ramalingam, Yi Cheng et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Y. Ohe Japan	4	289	240	122	77	35	12	326
Masayuki Yasugi Japan	9	241 0.8×	240 1.0×	132 1.1×	48 0.6×	38 1.1×	22	358
A. Todd Japan	5	323 1.1×	252 1.1×	124 1.0×	84 1.1×	30 0.9×	8	343
M.R. García Campelo Spain	9	301 1.0×	284 1.2×	119 1.0×	90 1.2×	32 0.9×	35	387
J.C.-H. Yang Taiwan	5	281 1.0×	263 1.1×	94 0.8×	46 0.6×	22 0.6×	12	353
Eric Sommers United States	10	310 1.1×	236 1.0×	164 1.3×	102 1.3×	32 0.9×	19	468
Janice J.N. Li Canada	9	219 0.8×	178 0.7×	114 0.9×	132 1.7×	30 0.9×	16	335
B.C. Cho South Korea	8	232 0.8×	204 0.8×	90 0.7×	47 0.6×	19 0.5×	33	280
Aurélie Swalduz France	11	200 0.7×	182 0.8×	126 1.0×	92 1.2×	34 1.0×	63	334
L. Paz-Ares Spain	9	215 0.7×	291 1.2×	97 0.8×	40 0.5×	38 1.1×	51	374
Adel Zaatar Australia	5	376 1.3×	328 1.4×	126 1.0×	105 1.4×	26 0.7×	9	476

Countries citing papers authored by Y. Ohe

Since Specialization

Citations

This map shows the geographic impact of Y. Ohe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Ohe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Ohe more than expected).

Fields of papers citing papers by Y. Ohe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Ohe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Ohe. The network helps show where Y. Ohe may publish in the future.

Co-authorship network of co-authors of Y. Ohe

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Ohe. A scholar is included among the top collaborators of Y. Ohe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Ohe. Y. Ohe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Katayama, Hiroshi, Junki Mizusawa, Haruhiko Fukuda, et al.. (2021). Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A). Japanese Journal of Clinical Oncology. 51(5). 685–692. 5 indexed citations

Barlési, Fabrice, Jennifer Moriatis Wolf, Robert C. Doebele, et al.. (2020). 385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. Annals of Oncology. 31. S1391–S1392. 3 indexed citations

Ramalingam, Suresh S., Yi Cheng, C. Zhou, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. viii740–viii740. 269 indexed citations breakdown →

Kirita, Keisuke, Shingo Matsumoto, Y. Ohe, et al.. (2017). Detectability of RET fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project: LC-SCRUM-Japan. Annals of Oncology. 28. v475–v475. 1 indexed citations

Nakamura, Atsushi, Hibiki Udagawa, Shingo Matsumoto, et al.. (2017). Prevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer. Annals of Oncology. 28. x126–x126. 3 indexed citations

Matsumoto, Shingo, Kiyotaka Yoh, Kadoaki Ohashi, et al.. (2016). Detectability of druggable gene fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project (LC-SCRUM-Japan). Annals of Oncology. 27. vi420–vi420.

Yamane, Yuki, Motoki Iwasaki, Akikazu Kawase, et al.. (2011). Impact of dietary habits on epidermal growth factor receptor (EGFR) mutation status of Japanese patients with lung adenocarcinomas.. Journal of Clinical Oncology. 29(15_suppl). 1567–1567. 1 indexed citations

Yamane, Yuki, Kanako Goto, Hirotsugu Kenmotsu, et al.. (2010). Clinicopathologic differences between lung cancer with EGFR gene major (exon 19 deletions and exon 21 L858R) and other minor mutations.. Journal of Clinical Oncology. 28(15_suppl). 7544–7544. 1 indexed citations

Yamamoto, Norio, Yuki Sato, Tomohide Tamura, et al.. (2008). Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX). Journal of Clinical Oncology. 26(15_suppl). 8034–8034. 1 indexed citations

10.

Gandara, David R., Y. Ohe, Yutaka Nishiwaki, et al.. (2004). Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials. Journal of Clinical Oncology. 22(14_suppl). 7007–7007. 25 indexed citations

11.

Yamamoto, Noboru, Tomohide Tamura, Y. Ohe, et al.. (1997). Chronopharmacology of etoposide given by low dose prolonged infusion in lung cancer patients.. PubMed. 17(1B). 669–72. 2 indexed citations

12.

Oshita, Fumihiro, Norio Yamamoto, Minoru Fukuda, et al.. (1995). Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro. Lung Cancer. 13(2). 220–220. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact